United States oncologists’clinical preferences regarding modes of medicinal cannabis use
作者机构:Harvard Medical SchoolDivision of Adult Psychosocial Oncology and Palliative CareDana Farber Cancer Institute450 Brookline AvenueBostonMA 02215USA Division of Medical ToxicologyDepartment of Emergency MedicineBrigham and Women’s VC/Koch Institute for Integrated Cancer Research/Massachusetts Institute of TechnologyThe Fenway Institute 75 Francis StreetBostonMA 02115USA Center for Survey ResearchUniversity of MassachusettsBoston 100 Morrissey BlvdBostonMA 02125USA
出 版 物:《Cancer Communications》 (癌症通讯(英文))
年 卷 期:2021年第41卷第6期
页 面:528-531页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:NIDA NIH HHS [K23 DA044874] Funding Source: Medline
摘 要:Dear Editor,Almost every state in the United States with a comprehensive medicinal cannabis(MC)law identifies cancer as a qualifying condition for MC use[1,2].A growing body of scientific literature indicates that cancer patients use MC for both symptom management(e.g.,pain,low appetite,fatigue,mood disturbance)and cancer-directed therapy[3,4].